糖尿病视网膜病变的药物治疗研究进展

doi:10.3969/j.issn.1674-8115.2024.07.003

上海交通大学学报（医学版） ›› 2024, Vol. 44 ›› Issue (7): 822-829.doi: 10.3969/j.issn.1674-8115.2024.07.003

• 转化医学研究前沿进展专题 • 上一篇

糖尿病视网膜病变的药物治疗研究进展

陈铭豪¹(), 刘沛雨¹, 王旋², 吴一想¹, 江玉瑾¹, 张朝阳¹(), 张敬法¹^,³()

^1.上海交通大学医学院附属第一人民医院眼科，上海 200080
^2.上海交通大学医学院附属新华医院眼科，上海 200092
^3.香港中文大学（深圳）国际眼科研究所，深圳 518000

收稿日期:2024-02-11 接受日期:2024-05-22 出版日期:2024-07-28 发布日期:2024-07-28
通讯作者: 张朝阳,张敬法 E-mail:cmh1054@163.com;chaoyang.zhang@shgh.cn;13917311571@139.com
作者简介:陈铭豪（2000—），男，博士生；电子信箱：cmh1054@163.com。第一联系人：#为共同通信作者。
基金资助:
国家自然科学基金(82171062)

Advances in drug therapy of diabetic retinopathy

CHEN Minghao¹(), LIU Peiyu¹, WANG Xuan², WU Yixiang¹, JIANG Yujin¹, ZHANG Chaoyang¹(), ZHANG Jingfa¹^,³()

^1.Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
^2.Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
^3.The International Eye Research Institute of The Chinese University of Hong Kong (Shenzhen), Shenzhen 518000, China

Received:2024-02-11 Accepted:2024-05-22 Online:2024-07-28 Published:2024-07-28
Contact: ZHANG Chaoyang,ZHANG Jingfa E-mail:cmh1054@163.com;chaoyang.zhang@shgh.cn;13917311571@139.com
Supported by:
National Natural Science Foundation of China(82171062)

摘要/Abstract

摘要：

糖尿病视网膜病变（diabetic retinopathy，DR）是糖尿病最常见的微血管并发症之一，已成为糖尿病患者失明和视力障碍的主要原因之一。DR的发病机制复杂，主要涉及炎症、氧化应激、神经血管性病变等诸多方面，为疾病治疗提供了潜在的干预靶点。当前，抗血管内皮生长因子（vascular endothelial growth factor，VEGF）药物是DR的一线治疗手段，主要针对疾病晚期阶段，但此时视网膜已经发生了不可逆的神经血管损伤及视功能降低。另外，仍有部分患者对抗VEGF治疗反应欠佳、甚至无反应。目前几乎没有针对疾病早期的干预手段，因此，迫切需要基于DR发病机制开发出新型的局部或全身疗法，能够对DR进行早期预防和治疗，并尽可能挽救患者视力。针对不同靶点的药物如抗炎药物（糖皮质激素、非甾体抗炎药）、神经营养和神经保护类药物、靶向生化途径类药物、抗氧化植物化合物、基因治疗类药物等在治疗效果上可以互相补偿，从而能够让更多DR患者获益。该文结合既往研究报道，对DR的发病机制、药物治疗方法以及潜在药物治疗靶点进行综述，旨在为临床治疗及相关研究提供参考。

关键词: 糖尿病视网膜病变, 炎症, 氧化应激, 血管内皮生长因子, 药物治疗

Abstract:

Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes and has become one of the leading causes of blindness and visual impairment in diabetes patients. The pathogenesis of DR is multifaceted, involving inflammation, oxidative stress, neurovascular abnormalities, and other factors that present potential targets for disease management interventions. Currently, anti-vascular endothelial growth factor (VEGF) drugs serve as the primary treatment for advanced stages of DR when irreversible neurovascular damage and visual impairment have occurred. Additionally, some patients show poor or no response to anti-VEGF treatment. There is a lack of early intervention options for the initial phases of the disease. Therefore, there is an urgent need to develop novel local or systemic therapies based on the underlying mechanisms of DR to enable early prevention and treatment with the aim of preserving patients′ vision. Medications targeting various pathways including anti-inflammatory agents (corticosteroids and nonsteroidal anti-inflammatory drugs), neurotrophic and neuroprotective drugs, drugs modulating biochemical pathways, antioxidant phytochemicals, and gene therapy can complement each other in terms of therapeutic effects to benefit a larger number of individuals affected by DR. This article reviews previous research reports on the pathogenesis, drug treatment methods, and potential therapeutic targets associated with DR in order to provide guidance for clinical practice.

Key words: diabetic retinopathy (DR), inflammation, oxidative stress, vascular endothelial growth factor (VEGF), drug therapy

中图分类号:

R774.1

陈铭豪, 刘沛雨, 王旋, 吴一想, 江玉瑾, 张朝阳, 张敬法. 糖尿病视网膜病变的药物治疗研究进展[J]. 上海交通大学学报（医学版）, 2024, 44(7): 822-829.

CHEN Minghao, LIU Peiyu, WANG Xuan, WU Yixiang, JIANG Yujin, ZHANG Chaoyang, ZHANG Jingfa. Advances in drug therapy of diabetic retinopathy[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 822-829.

参考文献 57

1	KANG Q Z, YANG C X. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J]. Redox Biol, 2020, 37: 101799.
2	KOLEVA-GEORGIEVA D N, SIVKOVA N P, TERZIEVA D. Serum inflammatory cytokines IL-1β, IL-6, TNF-α and VEGF have influence on the development of diabetic retinopathy[J]. Folia Med, 2011, 53(2): 44-50.
3	SADIKAN M Z, NASIR N A A, AGARWAL R, et al. Protective effect of palm oil-derived tocotrienol-rich fraction against retinal neurodegenerative changes in rats with streptozotocin-induced diabetic retinopathy[J]. Biomolecules, 2020, 10(4): 556.
4	SADIKAN M Z, ABDUL NASIR N A, BAKAR N S, et al. Tocotrienol-rich fraction reduces retinal inflammation and angiogenesis in rats with streptozotocin-induced diabetes[J]. BMC Complement Med Ther, 2023, 23(1): 179.
5	BARBER A J, GARDNER T W, ABCOUWER S F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2011, 52(2): 1156-1163.
6	METTU P S, ALLINGHAM M J, COUSINS S W. Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities[J]. Prog Retin Eye Res, 2021, 82: 100906.
7	EICHENBAUM D A, AHMED A, HIYA F. Ranibizumab port delivery system: a clinical perspective[J]. BMJ Open Ophthalmol, 2022, 7(1): e001104.
8	REGILLO C, BERGER B, BROOKS L, et al. Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results[J]. Ophthalmology, 2023, 130(7): 735-747.
9	SHUGHOURY A, BHATWADEKAR A, JUSUFBEGOVIC D, et al. The evolving therapeutic landscape of diabetic retinopathy[J]. Expert Opin Biol Ther, 2023, 23(10): 969-985.
10	BROWN D M, EMANUELLI A, BANDELLO F, et al. KESTREL and KITE: 52-week results from two phase Ⅲ pivotal trials of brolucizumab for diabetic macular edema[J]. Am J Ophthalmol, 2022, 238: 157-172.
11	ABU SERHAN H, TAHA M J J, ABUAWWAD M T, et al. Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis[J]. Semin Ophthalmol, 2024, 39(4): 251-260.
12	JOUSSEN A M, RICCI F, PARIS L P, et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data[J]. Eye, 2021, 35(5): 1305-1316.
13	SAHNI J, PATEL S S, DUGEL P U, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial[J]. Ophthalmology, 2019, 126(8): 1155-1170.
14	WYKOFF C C, ABREU F, ADAMIS A P, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials[J]. Lancet, 2022, 399(10326): 741-755.
15	DUGEL P U, BOYER D S, ANTOSZYK A N, et al. Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration[J]. Ophthalmol Retina, 2020, 4(3): 250-263.
16	GONZALEZ-CORTES J H, MARTINEZ-PACHECO V A, GONZALEZ-CANTU J E, et al. Current treatments and innovations in diabetic retinopathy and diabetic macular edema[J]. Pharmaceutics, 2022, 15(1): 122.
17	HUSSAIN R M, SHAUKAT B A, CIULLA L M, et al. Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration[J]. Drug Des Devel Ther, 2021, 15: 2653-2665.
18	CHANDRASEKARAN P R, MADANAGOPALAN V G. KSI-301: antibody biopolymer conjugate in retinal disorders[J]. Ther Adv Ophthalmol, 2021, 13: 25158414211027708.
19	BOYER D S, YOON Y H, BELFORT R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(10): 1904-1914.
20	WEI W B, CHEN Y X, HU B J, et al. Multicenter, prospective, randomized study of dexamethasone intravitreal implant in patients with center-involved diabetic macular edema in the Asia-Pacific region[J]. Clin Ophthalmol, 2021, 15: 4097-4108.
21	MUSHTAQ Y, MUSHTAQ M M, GATZIOUFAS Z, et al. Intravitreal fluocinolone acetonide implant (ILUVIEN^®) for the treatment of retinal conditions. A review of clinical studies[J]. Drug Des Devel Ther, 2023, 17: 961-975.
22	SINGER M A, SHETH V, MANSOUR S E, et al. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study[J]. Ophthalmology, 2022, 129(6): 605-613.
23	GABR A F, KAMEL M F, ELBARAWY A A. Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema[J]. Int Ophthalmol, 2023, 43(9): 3219-3226.
24	ELBENDARY A, ELKANNISHY A H. Intravitreal diclofenac versus intravitreal bevacizumab in persistent diabetic macular edema: anatomical and functional outcome[J]. Saudi J Ophthalmol, 2018, 32(4): 303-309.
25	FEIZI S, ALEMZADEH-ANSARI M, KARIMIAN F, et al. Use of erythropoietin in ophthalmology: a review[J]. Surv Ophthalmol, 2022, 67(2): 427-439.
26	SAMSON F P, HE W L, SRIPATHI S R, et al. Dual switch mechanism of erythropoietin as an antiapoptotic and pro-angiogenic determinant in the retina[J]. ACS Omega, 2020, 5(33): 21113-21126.
27	QI Y X, SU X J, WEI L L, et al. Erythropoietin inhibits apoptosis of retinal ganglion cells induced by high glucose through JNK signaling pathway[J]. J Biol Regul Homeost Agents, 2021, 35(2): 547-557.
28	ENTEZARI M, FLAVARJANI Z K, RAMEZANI A, et al. Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial[J]. Graefes Arch Clin Exp Ophthalmol, 2019, 257(11): 2375-2380.
29	REID G, LOIS N. Erythropoietin in diabetic retinopathy[J]. Vision Res, 2017, 139: 237-242.
30	CANNING P, O′LEARY O, ALLEN L D, et al. ARA290 (cibinetide) treatment confers neuroprotective effects in diabetic retinopathy, through modulation of inflammatory mediators[J]. Invest Ophthalmol Vis Sci, 2019, 60(9): 2720.
31	LOIS N, GARDNER E, MCFARLAND M, et al. A phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema[J]. J Clin Med, 2020, 9(7): 2225.
32	AMATO R, DAL MONTE M, CERVIA D, et al. Neural degeneration mechanisms in diabetic retinopathy: the role of apoptosis and autophagy[J]. Acta Ophthalmol, 2017, 95(S259). DOI: 10.1111/j.1755-3768.2017.0F064.
33	VILLARROEL M, CIUDIN A, HERNÁNDEZ C, et al. Neurodegeneration: an early event of diabetic retinopathy[J]. World J Diabetes, 2010, 1(2): 57-64.
34	HERNÁNDEZ C, SIMÓ R. Somatostatin replacement: a new strategy for treating diabetic retinopathy[J]. Curr Med Chem, 2013, 20(26): 3251-3257.
35	MAZZEO A, ARROBA A I, BELTRAMO E, et al. Somatostatin protects human retinal pericytes from inflammation mediated by microglia[J]. Exp Eye Res, 2017, 164: 46-54.
36	SIMÓ R, HERNÁNDEZ C, PORTA M, et al. Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy: results of the EUROCONDOR clinical trial[J]. Diabetes, 2019, 68(2): 457-463.
37	JULIUS A, HOPPER W. A non-invasive, multi-target approach to treat diabetic retinopathy[J]. Biomed Pharmacother, 2019, 109: 708-715.
38	SENTHILKUMARI S, SHARMILA R, CHIDAMBARANATHAN G, et al. Epalrestat, an aldose reductase inhibitor prevents glucose-induced toxicity in human retinal pigment epithelial cells in vitro[J]. J Ocul Pharmacol Ther, 2017, 33(1): 34-41.
39	TOYODA F, TANAKA Y, OTA A, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats[J]. J Diabetes Res, 2014, 2014: 672590.
40	LU Z W, FAN B, LI Y Z, et al. RAGE plays key role in diabetic retinopathy: a review[J]. Biomed Eng Online, 2023, 22(1): 128.
41	RAMIS R, ORTEGA-CASTRO J, CABALLERO C, et al. How does pyridoxamine inhibit the formation of advanced glycation end products? The role of its primary antioxidant activity[J]. Antioxidants, 2019, 8(9): 344.
42	XU J, CHEN L J, YU J, et al. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy[J]. Cell Physiol Biochem, 2018, 48(2): 705-717.
43	VAN DEN EYNDE M D G, HOUBEN A J H M, SCHEIJEN J L J M, et al. Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: a randomized double-blind placebo-controlled trial[J]. Diabetes Obes Metab, 2023, 25(5): 1280-1291.
44	BAGGE S L, FOTHERINGHAM A K, LEUNG S S, et al. Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes[J]. Med Res Rev, 2020, 40(4): 1200-1219.
45	DEISSLER H L, LANG G E. The protein kinase C inhibitor: ruboxistaurin[J]. Dev Ophthalmol, 2016, 55: 295-301.
46	LAM C, LOW J Y, TRAN P T, et al. The hexosamine biosynthetic pathway and cancer: current knowledge and future therapeutic strategies[J]. Cancer Lett, 2021, 503: 11-18.
47	SEMBA R D, HUANG H, LUTTY G A, et al. The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy[J]. Proteomics Clin Appl, 2014, 8(3/4): 218-231.
48	VAIDYANATHAN K, WELLS L. Multiple tissue-specific roles for the O-GlcNAc post-translational modification in the induction of and complications arising from type Ⅱ diabetes[J]. J Biol Chem, 2014, 289(50): 34466-34471.
49	GUREL Z, SHEIBANI N. O-Linked β-N-acetylglucosamine (O- GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy[J]. Clin Sci, 2018, 132(2): 185-198.
50	WANG Y X, ESHWARAN R, BECK S C, et al. Contribution of the hexosamine biosynthetic pathway in the hyperglycemia-dependent and -independent breakdown of the retinal neurovascular unit[J]. Mol Metab, 2023, 73: 101736.
51	DIERSCHKE S K, TORO A L, BARBER A J, et al. Angiotensin-(1‒7) attenuates protein O-GlcNAcylation in the retina by EPAC/Rap1-dependent inhibition of O-GlcNAc transferase[J]. Invest Ophthalmol Vis Sci, 2020, 61(2): 24.
52	PETERSON S B, HART G W. New insights: a role for O-GlcNAcylation in diabetic complications[J]. Crit Rev Biochem Mol Biol, 2016, 51(3): 150-161.
53	SILVA K C, ROSALES M A, HAMASSAKI D E, et al. Green tea is neuroprotective in diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2013, 54(2): 1325-1336.
54	ABU-AMERO K K, KONDKAR A A, CHALAM K V. Resveratrol and ophthalmic diseases[J]. Nutrients, 2016, 8(4): 200.
55	CHEN Y H, MENG J, LI H, et al. Resveratrol exhibits an effect on attenuating retina inflammatory condition and damage of diabetic retinopathy via PON1[J]. Exp Eye Res, 2019, 181: 356-366.
56	LANDON R, GUEGUEN V, PETITE H, et al. Impact of astaxanthin on diabetes pathogenesis and chronic complications[J]. Mar Drugs, 2020, 18(7): 357.
57	GELFMAN C M, GRISHANIN R, BENDER K O, et al. Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema[J]. J Ocul Pharmacol Ther, 2021, 37(3): 181-190.

[1]	曾德洁, 陈增辉, 丁乾坤, 孙夏青, 孙琪, 赵士兵. 天然来源的多糖在干预神经发育障碍中的应用前景[J]. 上海交通大学学报（医学版）, 2024, 44(6): 779-787.
[2]	郑晓峰, 徐凌. 多发性肌炎/皮肌炎相关间质性肺病治疗的研究进展[J]. 上海交通大学学报（医学版）, 2024, 44(4): 531-536.
[3]	郑梦奕, 毛家亮, 邹治国, 张瑞雷, 张厚, 李世光. 全身免疫炎症指数及躯体化症状评分对首发心梗PCI术后发生院内主要不良心血管事件的预测价值[J]. 上海交通大学学报（医学版）, 2024, 44(3): 334-341.
[4]	卢雨涵, 石亚红, 龙满美, 王子, 吴颖为. 氧化纳米铈清除活性氧改善DSS诱导的小鼠结肠炎疾病活动度的研究[J]. 上海交通大学学报（医学版）, 2024, 44(1): 35-42.
[5]	贾君杰, 邢海帆, 张群子, 刘奇烨, 汪年松, 范瑛. 缺氧诱导因子-1α抑制剂YC-1改善糖尿病肾病小鼠肾脏损伤的机制研究[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1089-1098.
[6]	金芳全, 樊成虎, 唐晓栋, 陈彦同, 齐兵献. 线粒体功能障碍与骨质疏松症相关性研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(6): 761-767.
[7]	陈瑾, 傅瑶. 人角膜内皮细胞自体再生的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(6): 775-780.
[8]	朱思宇, 董晓艳. 哮喘儿童小气道功能障碍的再认识[J]. 上海交通大学学报（医学版）, 2023, 43(4): 500-506.
[9]	吴昭瑜, 许之珏, 蒲蕻吉, 王新, 陆信武. 神经损伤诱导蛋白1的生理功能及其在相关疾病中的作用[J]. 上海交通大学学报（医学版）, 2023, 43(3): 358-364.
[10]	谢莎莎, 吕叶辉, 林涧. 四面体框架核酸在医学领域的应用与研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(3): 380-384.
[11]	过丽强, 赵世天, 舒冰. Notch信号通路在骨折愈合过程中作用的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(2): 222-229.
[12]	陈子旋, 李东, 刘敏. 细胞焦亡在老年男性良性前列腺增生中的作用综述[J]. 上海交通大学学报（医学版）, 2023, 43(12): 1569-1576.
[13]	陆若玉, 康文慧, 赵安达, 陆兆辉, 李生慧. 褪黑素与妊娠期高血压疾病的关系研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1297-1303.
[14]	吴振恺, 邓博, 潘瑜, 丁峰. 酰基羧酸水解酶在疾病中的作用及机制研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(1): 101-107.
[15]	杨文倩, 陈迟琪, 赵路, 曹力元, 夏一秋, 卢智刚, 郑俊克. 免疫抑制性受体LILRB2促进新型冠状病毒刺突蛋白介导的炎症过程[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1188-1196.

糖尿病视网膜病变的药物治疗研究进展

Advances in drug therapy of diabetic retinopathy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 57

相关文章 15

编辑推荐

Metrics